IOVANCE BIOTHERAPEUTICS, INC. Contracts & Agreements

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended (Filed With SEC on August 8, 2024)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on August 8, 2024)

Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (Filed With SEC on May 9, 2024)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on May 9, 2024)

Underwriting Agreement, dated as of February 20, 2024 among Iovance Biotherapeutics, Inc., Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (Filed With SEC on February 20, 2024)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on November 7, 2023)

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended (Filed With SEC on November 7, 2023)

Underwriting Agreement, dated as of July 10, 2023 among Iovance Biotherapeutics, Inc., Goldman Sachs & Co. LLC and Jefferies LLC (Filed With SEC on July 11, 2023)

Open Market Sale Agreement dated June 16, 2023, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on June 16, 2023)

Open Market Sale Agreement dated November 18, 2022, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on November 18, 2022)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on August 4, 2022)

Form of Deferred Stock Unit Notice and Deferred Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 4, 2022)

Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (Filed With SEC on February 24, 2022)

Third Amendment to the Lease Agreement, effective as of November 1, 2021, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on February 24, 2022)

Iovance Biotherapeutics, Inc. 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2021 Inducement Plan (Filed With SEC on September 23, 2021)

Amended and Restated Patent License Agreement, by and between Iovance Biotherapeutics, Inc. and the National Institutes of Health (Filed With SEC on August 5, 2021)

Form of Stock Unit Notice and Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)

Form of Nonqualified Stock Option Award Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)

Executive Employment Agreement, effective as of March 15, 2021, by and between Igor Bilinsky, Ph.D. and Iovance Biotherapeutics, Inc (Filed With SEC on May 6, 2021)

Executive Employment Agreement, effective as of December 14, 2020, by and between Jean-Marc Bellemin and Iovance Biotherapeutics, Inc (Filed With SEC on February 25, 2021)

Lease Agreement dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and ARE-San Francisco No. 63, LLC (Filed With SEC on February 9, 2021)

Second Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)

First Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on February 9, 2021)

Open Market Sale Agreement dated February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC (Filed With SEC on February 9, 2021)

Second Amendment to the Lease Agreement, effective as of June 30, 2020, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on August 6, 2020)

Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc. and Timothy Morris (Filed With SEC on August 6, 2020)

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on June 9, 2020)

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on June 9, 2020)

Underwriting Agreement dated May 28, 2020 (Filed With SEC on May 29, 2020)

Description of Securities (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Non-Qualified Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Non-Qualified Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Incentive Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)

Form of Non-Qualified Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)

First Amendment to the Office Lease, effective as of June 19, 2019, between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on November 4, 2019)

First Amendment to the Lease Agreement, effective as of August 20, 2019, between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on November 4, 2019)

Executive Employment Agreement effective as of July 18, 2019, by and between Friedrich-Reinhard Graf Finck von Finckenstein, M.D (Filed With SEC on August 1, 2019)

First Amendment to the Lease Agreement dated as of June 19, 2019, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on June 21, 2019)

Lease Agreement dated as of May 28, 2019, by and between Iovance Biotherapeutics, Inc. and 300 Rouse Boulevard, LLC (Filed With SEC on June 3, 2019)

Office Lease, effective as of October 19, 2018, between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (Filed With SEC on October 25, 2018)

Underwriting Agreement dated October 11, 2018 (Filed With SEC on October 12, 2018)

Form of ISO Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 7, 2018)

Form of NQSO Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 7, 2018)

Specimen of Stock Certificate (Filed With SEC on March 12, 2018)

Amended and Restated Manufacturing Services Agreement, dated December 18, 2017, between WuXi AppTec, Inc. and Iovance Biotherapeutics, Inc (Filed With SEC on March 12, 2018)

Executive Employment Agreement, effective September 30, 2016, between Frederick G. Vogt and Lion Biotechnologies, Inc (Filed With SEC on March 12, 2018)

First Amendment to the Strategic Alliance Agreement between Lion Biotechnologies, Inc., and The University of Texas M.D. Anderson Cancer Center, effective August 2, 2017 (Filed With SEC on March 12, 2018)

Second Amendment to the Strategic Alliance Agreement between Iovance Biotherapeutics, Inc., and The University of Texas M.D. Anderson Cancer Center, effective February 16, 2018 (Filed With SEC on March 12, 2018)

Underwriting Agreement dated January 24, 2018 (Filed With SEC on January 25, 2018)

Executive Employment Agreement, effective August 14, 2017, between Timothy E. Morris and Registrant (Filed With SEC on November 2, 2017)

Underwriting Agreement dated September 20, 2017 (Filed With SEC on September 21, 2017)

Consulting Agreement, dated September 14, 2017, between Iovance Biotherapeutics, Inc. and Iain Dukes, D. Phil (Filed With SEC on September 15, 2017)

Text Marked By [* * *] Has Been OmittedPursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. STRATEGIC ALLIANCE... (Filed With SEC on August 3, 2017)

PLANOF CONVERSION OF LION BIOTECHNOLOGIES, INC. A Nevada Corporation INTO LION BIOTECHNOLOGIES, INC. A Delaware Corporation (Filed With SEC on June 2, 2017)

SUBLEASE AGREEMENT (Filed With SEC on May 1, 2017)

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2017)

Text Marked By [* **] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The SecuritiesAnd Exchange Commission. MANUFACTURING SERVICES... (Filed With SEC on March 9, 2017)

LION BIOTECHNOLOGIES, INC. 2017 CORPORATE GOALS—CASH BONUS PLAN (Filed With SEC on March 9, 2017)

Text Marked By [* * *] Has Been OmittedPursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. EXCLUSIVE AND... (Filed With SEC on November 4, 2016)

INDEMNIFICATION AGREEMENT (Filed With SEC on November 4, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on October 3, 2016)

Amendment #2 Cooperative Research and Development Agreement# 02734 (Filed With SEC on August 31, 2016)

Text Marked By [* * *] Has BeenOmitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. EXECUTIVE EMPLOYMENT... (Filed With SEC on August 9, 2016)

OFFICE LEASE (Filed With SEC on August 8, 2016)

AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on July 1, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 3, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 3, 2016)

SEVERANCE AGREEMENT AND GENERAL RELEASE (Filed With SEC on June 3, 2016)

BOARD ADVISER AGREEMENT (Filed With SEC on June 3, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 9, 2016)

NATIONAL INSTITUTES OF HEALTH FIRST AMENDMENT TO L-107-2015/0 (Filed With SEC on November 6, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 10, 2015)

4,750,000 Shares Lion Biotechnologies, Inc. UNDERWRITING AGREEMENT (Filed With SEC on May 4, 2015)

AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on April 17, 2015)

Text Marked By [* * *] Has Been Omitted PursuantTo A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. THENational... (Filed With SEC on March 16, 2015)

Text MarkedBy [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities AndExchange Commission. THENational Institutes... (Filed With SEC on March 16, 2015)

8,000,000 Shares Lion Biotechnologies, Inc. UNDERWRITING AGREEMENT (Filed With SEC on March 3, 2015)

Amendment#1 CooperativeResearch and Development Agreement # 02734 “CooperativeResearch and Development Agreement for the Developmentand Evaluation of the NCI Proprietary... (Filed With SEC on January 27, 2015)

5,217,392 Shares Lion Biotechnologies, Inc. UNDERWRITING AGREEMENT (Filed With SEC on December 22, 2014)

Executive Employment Agreement, dated August 21, 2014, by and among Lion Biotechnologies, Inc. and Dr. Elma Hawkins (Filed With SEC on August 26, 2014)

LEASE (Filed With SEC on August 8, 2014)

Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. EXCLUSIVE LICENSE... (Filed With SEC on August 8, 2014)

REPLACEMENT EMPLOYMENT AGREEMENT (Filed With SEC on May 19, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on January 7, 2014)

LION BIOTECHNOLOGIES, INC. Warrant To Purchase Common Stock (Filed With SEC on October 31, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on October 31, 2013)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 31, 2013)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on July 25, 2013)

DIRECTOR STOCK AWARD AGREEMENT (Filed With SEC on July 25, 2013)

SETTLEMENT AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS (Filed With SEC on June 25, 2013)

STOCK PURCHASE AGREEMENT (Filed With SEC on May 29, 2013)

EXCHANGE AGREEMENT (Filed With SEC on May 29, 2013)

MATURITY DATE EXTENSION (Filed With SEC on October 4, 2012)

MATURITY DATE EXTENSION (Filed With SEC on July 6, 2012)

SUBSCRIPTION AGREEMENT (Filed With SEC on May 11, 2012)

SECURED PROMISSORY NOTE (Filed With SEC on May 11, 2012)

PROMISSORY NOTE (Filed With SEC on April 10, 2012)

AmendmentNo. 8 to TrancheA Senior Secured Convertible Notes and Tranche B Senior Secured Convertible Notes (Filed With SEC on April 5, 2012)

AmendmentNo. 5 to TrancheA Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock (Filed With SEC on April 5, 2012)

COMMON STOCK PURCHASE WARRANT (Filed With SEC on March 30, 2012)

SECOND AMENDMENT TO CONSULTING AGREEMENTDATED FEBRUARY 15, 2011 BY AND BETWEEN EMMES GROUP CONSULTING LLC AND GENESIS BIOPHARMA, INC. (Filed With SEC on March 30, 2012)

AMENDMENT TO CONSULTING AGREEMENT DATEDFEBRUARY 15, 2011 BY AND BETWEEN EMMES GROUP CONSULTING LLC AND GENESIS BIOPHARMA, INC. (Filed With SEC on March 30, 2012)

CONSULTING AGREEMENT (Filed With SEC on March 30, 2012)

MANUFACTURING SERVICES AGREEMENT (Filed With SEC on March 30, 2012)

AmendmentNo. 6 to TrancheA Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (Filed With SEC on March 6, 2012)

AmendmentNo. 4 to TrancheA Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock (Filed With SEC on March 6, 2012)

AmendmentNo. 5 to TrancheA Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (Filed With SEC on February 6, 2012)

Amendment No. 2 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (Filed With SEC on December 22, 2011)

Amendment No. 2 to Tranche A Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock (Filed With SEC on December 22, 2011)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE COVER PAGE (Filed With SEC on December 13, 2011)

AMENDMENT NO. 1 TO TRANCHE A SENIOR UNSECURED CONVERTIBLE NOTES AND TRANCHE B SENIOR UNSECURED CONVERTIBLE NOTES (Filed With SEC on December 5, 2011)

AMENDMENT NO. 1 TO TRANCHE A WARRANTS TO PURCHASE COMMON STOCK AND TRANCHE B WARRANTS TO PURCHASE COMMON STOCK (Filed With SEC on December 5, 2011)

PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on November 29, 2011)

LETTER OF INTENT (Filed With SEC on November 21, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on October 20, 2011)

GENESIS BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN (Filed With SEC on October 20, 2011)

GENESIS BIOPHARMA, INC. OPTION CERTIFICATE (Filed With SEC on October 20, 2011)

GENESIS BIOPHARMA, INC. OPTION CERTIFICATE (Non-Qualified Stock Option) (Filed With SEC on October 20, 2011)

Text Marked By [****Redacted****] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. PUBLIC... (Filed With SEC on October 13, 2011)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE COVER PAGE (Filed With SEC on October 11, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 29, 2011)

Genesis Biopharma, Inc. Tranche A Senior Unsecured Convertible Note (Filed With SEC on July 29, 2011)

Genesis Biopharma, Inc. Tranche A Warrant To Purchase Common Stock (Filed With SEC on July 29, 2011)

ESCROW AGREEMENT (Filed With SEC on July 29, 2011)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 29, 2011)

Genesis Biopharma, Inc. Tranche B Senior Unsecured Convertible Note (Filed With SEC on July 29, 2011)

Genesis Biopharma, Inc. Tranche B Warrant To Purchase Common Stock (Filed With SEC on July 29, 2011)

Genesis Biopharma, Inc. Placement Agent Warrant To Purchase Common Stock (Filed With SEC on July 29, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 22, 2011)

CLASS C COMMON STOCK PURCHASE WARRANT (Filed With SEC on April 22, 2011)

PRIVATEPLACEMENT SUBSCRIPTION AGREEMENT (Filed With SEC on January 3, 2011)

PRIVATEPLACEMENT SUBSCRIPTION AGREEMENT (Filed With SEC on October 28, 2010)

COMMONSTOCK PURCHASE WARRANT SERIESA WARRANT GENESISBIOPHARMA, INC. (Filed With SEC on September 23, 2010)

COMMONSTOCK PURCHASE WARRANT SERIESBWARRANT GENESISBIOPHARMA, INC. (Filed With SEC on September 23, 2010)

PRIVATEPLACEMENT SUBSCRIPTION AGREEMENT (Filed With SEC on September 23, 2010)

DATED 15TH MARCH2010 (1)CANCER RESEARCH TECHNOLOGY LIMITED AND (2)GENESIS BIOPHARMA, INC. (Filed With SEC on July 6, 2010)

GENESISBIOPHARMA, INC. 2010EQUITY COMPENSATION PLAN I.ESTABLISHMENTOF PLAN; DEFINITIONS (Filed With SEC on March 31, 2010)

GENESIS BIOPHARMA, INC. STOCK OPTIONAGREEMENT (Filed With SEC on March 31, 2010)

Category

Industry

Companies

Contracts

IOVANCE BIOTHERAPEUTICS, INC. Contracts & Agreements